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EnzalutamideStandard ﬁrst-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is docetaxel
plus prednisone; however, patients will usually experience disease progression during or after docetaxel
treatment due to inherent or acquired resistance. Before 2010, second-line options for mCRPC were lim-
ited. However, cabazitaxel, abiraterone acetate and enzalutamide have since been approved for patients
with mCRPC whose disease has progressed during or after receiving docetaxel, based on the Phase III tri-
als TROPIC, COU-AA-301 and AFFIRM. In all three trials, an overall survival beneﬁt (primary endpoint)
was seen in the experimental arm compared with the control arm: 15.1 vs. 12.7 months for cabazitaxel
plus prednisone compared with mitoxantrone plus prednisone in TROPIC (hazard ratio [HR] 0.70;
P < 0.0001); 14.8 vs. 10.9 months for abiraterone acetateplus prednisone compared with placebo plus
prednisone in COU-AA-301 (HR 0.65; P < 0.001); and 18.4 vs. 13.6 months for enzalutamide compared
with placebo alone in AFFIRM (0.63; P < 0.001). However, differences in patient populations, comparators,
and selection and/or deﬁnition of secondary endpoints make it difﬁcult to draw direct cross-trial compar-
isons. Radium-223 dichloride has also been approved for patients with mCRPC with metastases to bone
but not other organs. To date, no comparative trials or sequencing studies with newer agents have been
performed. Without such data, treatment decisions must be based on evaluation of the existing evidence.
This commentary compares and contrasts study designs and key data from each of these Phase III trials,
and also discusses recent and ongoing clinical trials with new agents in the ﬁrst- and second-line settings
in mCRPC.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Globally, prostate cancer is the second most frequently diag-
nosed cancer in men and is a major cause of mortality, represent-
ing 258,000 deaths in 2008 [1]. Although localized prostate cancer
may be successfully treated with radiotherapy or surgery, manypatients will develop metastatic disease [2–4]. Standard treatment
for patients with metastatic prostate cancer is androgen-depriva-
tion therapy; however, most patients will eventually develop resis-
tance leading to disease progression (metastatic castration-
resistant prostate cancer [mCRPC]). The introduction of highly
effective novel therapies has resulted in increased overall survival
(OS) in patients with mCRPC, from approximately 9–18 months [4]
to >30 months in patients enrolled in recent clinical trials and ex-
panded-access programs [5].
For patients with mCRPC, docetaxel (75 mg/m2 every 3 weeks)
was the ﬁrst agent to demonstrate a survival beneﬁt, and docetaxel
plus prednisone (10 mg orally, daily) is the standard ﬁrst-line ther-
apy recommended by international guidelines for patients with
symptomatic mCRPC who are suitable candidates for chemother-
apy [2–4]. In randomized Phase III trials, docetaxel-based treat-
ment showed a median OS beneﬁt compared with mitoxantrone
of 2–3 months, which was similar across subgroups (including
both 668 and P69 years, both presence and absence of visceral
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tion, prostate-speciﬁc antigen (PSA) response rates of 45–50%, an
objective tumor response rate of 12–17% and an improvement in
quality of life (QoL) compared with mitoxantrone were observed
(P < 0.01) [6–8]. However, patients will usually experience disease
progression either during or after receiving docetaxel regimens,
due to resistance, either inherent or acquired through a number
of different mechanisms [9,10]. In one study investigating a doce-
taxel-based regimen, the median time from ﬁrst docetaxel dose to
disease progression was 6.3 months [9].
Before 2010, second-line treatment options for mCRPC were-
limited, with no beneﬁts observed in terms of OS. Since 2010, how-
ever, three therapies have been approved for patients with mCRPC
whose disease has progressed during or after receiving docetaxel:
cabazitaxel, a novel tubulin-binding taxane (FDA approval in
2010; EMA approval in 2011) [11,12]; abiraterone acetate (AA),
an oral androgen biosynthesis inhibitor (FDA and EMA approval
in 2011) [13,14]; and enzalutamide, an oral androgen receptor
antagonist (formerly known as MDV3100; FDA approval in 2012)
[15]. Currently, cabazitaxel and AA are recommended in the Euro-
pean Association of Urology (EAU) and National Comprehensive
Cancer Network (NCCN) guidelines as second-line options in this
setting [2,4]. In addition, radium-223 dichloride, a novelalpha-
emitting radiopharmaceutical agent that targets bone metastases
owing to its chemical similarity to calcium, has recently been ap-
proved by the FDA for use in patients with mCRPC with symptom-
atic bone metastases and no known visceral metastatic disease.
This agent demonstrated positive results compared with placebo
in the Phase III ALSYMPCA trial in patients with mCRPC with bone
metastases [16,17]. Based on the enrollment criteria for the ALS-
YMPCA study and efﬁcacy data currently available, it is likely that
radium-223 dichloride will be used both in patients with prior
docetaxel therapy and in those who are not sufﬁciently ﬁt to re-
ceive chemotherapy [16,17]. However, because this agent is not
approved speciﬁcally in the second-line setting, it is not discussed
in detail within this manuscript.
To date, no comparative trialsor sequencing studies with newer
agents have been performed. In their absence, comparison of study
designs and data from the pivotal Phase III trials can help to deter-
mine which agents are suitable for patients with different charac-
teristics in second-line mCRPC. However, direct comparisons of
studies are difﬁcult when there are subtle differences in patient
populations and in deﬁnitions of either treatment response or fail-
ure. This commentary compares and contrasts study designs and
key data from each agent in patients with mCRPC whose disease
has progressed during or following treatment with docetaxel.Overview of Phase III trials of agents recently approved for
second-line treatment of mCRPC
Cabazitaxel, AA and enzalutamide were evaluated in patients
with mCRPC with disease progression during or after docetaxel
treatment in separate randomized Phase III trials – TROPIC, COU-
AA-301 and AFFIRM, respectively (Table 1).Cabazitaxel (TROPIC)
Cabazitaxel was the ﬁrst agent to demonstrate improved sur-
vival post-docetaxel in mCRPC patients. The approval of cabazit-
axel was based on the TROPIC study, a randomized, open-label,
Phase III trial in 755 patients with mCRPC whose disease had pro-
gressed during or after treatment with a docetaxel-containing reg-
imen (TROPIC; Table 1) [18]. Patients were randomized (1:1) to
cabazitaxel (25 mg/m2 1-h intravenous [IV] infusion every
3 weeks) plus prednisone (10 mg daily) or mitoxantrone (12 mg/m2 IV infusion every 3 weeks) plus prednisone (10 mg daily). Eligi-
ble patients had pathologically proven prostate cancer, previous
and ongoing castration by orchiectomy or luteinizing hormone-
releasing hormone agonists, or both, and an Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of 0–2. Patients
with measurable disease were required to have documented dis-
ease progression by Response Evaluation Criteria in Solid Tumors
(RECIST) withP1 visceral or soft-tissue metastatic lesion. Patients
with non-measurable disease were required to have rising serum
PSA concentrations (at least two consecutive increases relative to
a reference value measured at least a week apart) or the appear-
ance of at least one new demonstrable radiographic lesion. The pri-
mary endpoint was OS; secondary endpoints included progression-
free survival (PFS), tumor response rate, PSA response rate and
time to tumor progression (Table 1). For PFS, progression was indi-
cated by any of PSA progression, tumor progression (radiologic evi-
dence by RECIST) or pain.
Abiraterone acetate (COU-AA-301)
AA was evaluated in COU-AA-301, a randomized, double-blind,
Phase III trial in 1195 patients with mCRPC who had previously re-
ceived docetaxel and had progressive disease (Table 1) [19]. In this
trial, patients were randomized (2:1) to AA (1 g orally, once daily)
plus prednisone (5 mg twice daily) or placebo plus prednisone
(5 mg twice daily). Eligible patients had histologically or cytologi-
cally conﬁrmed prostate cancer, ongoing androgen deprivation,
with a serum testosterone level of 50 ng per deciliter or less
(62.0 nmol per liter), and an ECOG PS of 0–2. Disease progression
was deﬁned according to the criteria of the Prostate Cancer Clinical
Trials Working Group (PCWG2) [20] (two consecutive increases in
PSA concentration over a reference value) or radiographic evidence
of disease progression in soft tissue or bone with or without dis-
ease progression on the basis of the PSA value. The primary end-
point was OS; secondary endpoints included PFS, PSA
progression, PSA response rate and QoL measures (Table 1). Before
completion, the study was unblinded at the request of the Inde-
pendent Data Monitoring Committee (IDMC) and patients receiv-
ing placebo were crossed over to receive active treatment [19].
Enzalutamide (AFFIRM)
Most recently approved by both the FDA (August 2012) and
EMA (June 2013), enzalutamide (160 mg orally, once daily) was
evaluated in AFFIRM, a randomized, double-blind, placebo-con-
trolled, Phase III trial, which included 1199 patients with mCRPC
who had previously been treated with docetaxel and had progres-
sive disease, and who were randomized (2:1) to enzalutamide or
placebo (Table 1) [21]. Patients had a histologically or cytologically
conﬁrmed diagnosis of prostate cancer, castrate levels of testoster-
one (<50 ng per deciliter [1.7 nmol per liter]) and an ECOG PS of 0–
2. Progressive disease was deﬁned according to PCWG2 [20] crite-
ria and included three increasing values for PSA or radiographically
conﬁrmed progression with or without a rise in the PSA level. The
primary endpoint was OS; secondary endpoints included PFS, time
to ﬁrst skeletal-related event (SRE), tumor response, PSA response
and QoL measures (Table 1). After initial positive results from this
trial, the study was terminated early at the request of the IDMC in
order to cross patients over from placebo to active treatment [21].
Evaluation of the TROPIC, COU-AA-301 and AFFIRM trials
Study designs
Both the COU-AA-301 [19] and AFFIRM [21] trials were placebo
controlled, in contrast to the TROPIC study [18], which compared
cabazitaxel with mitoxantrone (a palliative chemotherapy). This
Table 1
Trial designs of the pivotal randomized Phase III trials of recently approved agents in metastatic castration-resistant prostate cancer progressing on or after docetaxel therapy.
Trial Agent(s) Comparator Treatment
regimen
Design Sites N Primary
endpoint
Main secondary endpoints
TROPIC [18] Cabazitaxel + prednisone(10 mg
daily) Randomized 1:1
Mitoxantrone
(12 mg/m2 IV
infusion every
3 weeks) +
prednisone
25 mg/m2 1-h
IV infusion
every 3 weeks
OL 146 sites
in 26
countries
755 OS  PFSb
 Time to tumor progression.
 Time to PSA progression.
 Time to pain progression.
 PSA response.
 Objective response.
 Pain response
COU-AA-301
[19]
Abiraterone + prednisone(5 mg
BID) Randomized 2:1
Placebo +
prednisone
1 g orally, OD DB 147 sites
in 13
countries
1195 OS  PSA response rate.
 Time to PSA progressionPFSc.
 QoL
AFFIRM [21] Enzalutamidea Randomized 2:1 Placebo 160 mg
orally, OD
DB 156 sites
in 15
countries
1199 OS  PFSc
 Time to ﬁrst SRE.
 PSA response.
 Objective soft tissue
response.
 QoL
BID, twice daily; DB, double blind; IV, intravenous; OD, once daily; OL, open label; OS, overall survival; PFS, progression-free survival; PSA, prostate-speciﬁc antigen; QoL,
quality of life; SRE, skeletal-related event.
a Use of prednisone or other glucocorticoids was permitted but not required.
b Progression deﬁned as either PSA progression, tumor progression or pain progression.
c Radiographic progression.
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In future, the use of placebo-controlled trials in the second-line
setting is unlikely to be possible on ethical grounds because the
standard of care has changed following the approval of the newer
agents [22].
In the TROPIC and COU-AA-301 trials, patients in both arms re-
ceived prednisone treatment. In contrast, in the AFFIRM trial, the
use of prednisone or other glucocorticoids was permitted, but
not required. This may result in a heterogeneous population in
terms of additional treatment administered, which may have an ef-
fect on the observed adverse events (AEs) and comparative efﬁcacy
between groups.
OS was the primary endpoint in all three trials; however, the
selection and deﬁnition of secondary endpoints varied across
the trials (Table 1). For example, in evaluation of PFS in the
TROPIC study, progression was deﬁned as any of the following:
PSA progression, tumor progression (radiologic evidence by RE-
CIST) or pain progression [18]. In contrast, the COU-AA-301 trial
and the AFFIRM trial deﬁned progression only as radiologic evi-
dence of tumor progression by RECIST. As a result, treatment
may have been stopped at an earlier point in the TROPIC study
compared with the other trials, resulting in a shorter duration
of treatment. The median duration of treatment was 8.0 and
8.3 months in the groups that received AA and enzalutamide,
respectively, compared with an average of six treatment cycles
(18 weeks) in patients receiving cabazitaxel in the TROPIC study
[18,19,21].
Other differences in secondary endpoints and exploratory anal-
yses included QoL and time to ﬁrst SRE, which were both recorded
in the COU-AA-301 and AFFIRM trials, but not the TROPIC trial.
However, the TROPIC trial evaluated relief of tumor-related symp-
toms, such as pain response and time to pain progression. In addi-
tion, pain-related assessments were extensively evaluated in the
COU-AA-301 and AFFIRM trials.Study population
Global representation. Compared with AFFIRM [21] and COU-AA-
301 [19], patients were enrolled into TROPIC [18] from a wider
variety of regions (26 countries for TROPIC vs. 15 for AFFIRM and
13 for COU-AA-301). Conversely, the COU-AA-301 [19] and AFFIRM
studies had larger patient populations than TROPIC [18] (N = 1195,
N = 1199 and N = 755, respectively).Baseline characteristics. All three trials recruited patients with pro-
gressive disease (including both patients with measurable progres-
sive disease by RECIST and patients with progressive disease based
on PSA increase), an ECOG PS of 0–2, and prior treatment with
docetaxel [18,19,21]. However, the percentage of patients discon-
tinuing prior treatment with docetaxel because of progression
was higher in the TROPIC trial than in the COU-AA-301 trial (63%
and 45% of patients who received cabazitaxel or AA, respectively)
[23,24], suggesting that the patient population in TROPIC poten-
tially had a higher degree of resistance to docetaxel. In addition,
the TROPIC and AFFIRM trials also included patients who were
more heavily pre-treated, with a subset having received >2 lines
of prior chemotherapy (6.0% in the cabazitaxel arm of TROPIC
and 3.1% in the enzalutamide arm of AFFIRM) [18,21], whereas
the COU-AA-301 trial included only patients who had received
either one or two previous regimens [19]. The TROPIC study also
documented the time from last prior therapy to progression and
from last prior therapy to randomization, providing a clearer
description of the extent of disease burden for the study popula-
tion [18,23]. The median time from last docetaxel dose to progres-
sion was 0.8 months and the majority (62%) of patients were
randomized to cabazitaxel within 6 months of their last docetaxel
treatment in the TROPIC trial [18,23]. Details of time from last prior
therapy to progression or randomization in the COU-AA-301 and
AFFIRM trial have not been published; therefore, less is known
about the population and the extent of their disease burden. More
detailed information on patient baseline characteristics may help
clinicians when selecting the most appropriate agent to use in spe-
ciﬁc patient populations.Efﬁcacy
In all three trials, an OS beneﬁt was seen in the experimental
arm compared with the control arm (Table 2). However, the im-
proved OS for cabazitaxel plus prednisone in TROPIC was com-
pared with mitoxantrone plus prednisone (15.1 vs. 12.7 months;
HR 0.70; 95% conﬁdence interval [CI] 0.59–0.83; P < 0.0001) [18],
whereas the improved OS for AA plus prednisone in COU-AA-301
was compared with placebo plus prednisone (14.8 vs. 10.9 months
[HR 0.65; 95% CI 0.54–0.77; P < 0.001]) [19], and for enzalutamide
in AFFIRM was compared with placebo alone (18.4 vs. 13.6 months
[HR 0.63; 95% CI 0.53–0.75; P < 0.001]) [21] (Table 2). It is impor-
tant to note that survival durations cannot be directly compared
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ian duration of follow-up was 12.8 months in TROPIC and COU-AA-
301, and 14.4 months in AFFIRM.
An updated analysis of OS in the COU-AA-301 trial has also been
published, in which the difference in median OS between the two
groups improved from 3.9 months [19] to 4.6 months (15.8 months
for AA plus prednisone vs. 11.2 months for placebo plus predni-
sone; HR 0.74; P < 0.0001; median follow-up 20.2 months) [25].
Subgroup analyses reveal potential differences in OS outcomes
depending on patient characteristics, although signiﬁcance is difﬁ-
cult to measure due to small patient numbers in some subgroups.
In particular, stratiﬁed analysis of the AFFIRM data found that
enzalutamide did not signiﬁcantly increase OS in patients with vis-
ceral metastases (poor prognosis) at baseline (HR 0.78; 95% CI
0.56–1.09) or in patients who had received two or more prior che-
motherapy regimens (HR 0.74; 95% CI 0.54–1.03) [21]. Cabazitaxel
also did not signiﬁcantly increase OS in patients with visceral dis-
ease (HR 0.88; 95% CI 0.64–1.22) [26]. However, patients with vis-
ceral metastases derived a signiﬁcant OS beneﬁt from AA (HR 0.70;
95% CI 0.52–0.94) in the COU-AA-301 trial [19]. In both the TROPIC
and COU-AA-301 trials, HRs in patients receiving more than one
prior therapy (HR 0.75; 95% CI 0.55–1.02 for TROPIC [18], HR
0.74; 95% CI 0.55–0.99 for COU-AA-301) [19] were similar to the
AFFIRM trial [21].
All three trials showed a signiﬁcant median OS improvement in
patients with ECOG PS 0–1 (HR 0.68; 95% CI 0.57–0.82 for TROPIC
[18], HR 0.64; 95% CI 0.53–0.78 for COU-AA-301 [19], HR 0.62; 95%
CI 0.52–0.75 for AFFFIRM) [21]. Conversely, the difference in med-
ian OS between treatment arms in patients with ECOG PS 2 did not
reach signiﬁcance in any of the trials (HR 0.81; 95% CI 0.48–1.38 for
TROPIC [18], HR 0.81; 95% CI 0.53–1.24 for COU-AA-301 [19], HR
0.65; 95% CI 0.39–1.07 for AFFIRM) [21]; however, sample sizes
for this subgroup were relatively small (n = 61, n = 127 and
n = 102 in TROPIC, COU-AA-301 and AFFIRM, respectively).
In all trials, a signiﬁcant OS beneﬁt versus comparator was
noted in patients P65 years [18,19,21]. In COU-AA-301 and AF-
FIRM, a signiﬁcant OS beneﬁt was also noted in patients <65 years
[19,21], whereas in TROPIC, although an OS beneﬁt for cabazitaxel
was indicated in patients aged <65 years, the difference between
treatment arms was not statistically signiﬁcant [18].
The TROPIC trial also analyzed OS beneﬁt by total prior doce-
taxel dose, with signiﬁcant beneﬁt versus mitoxantrone noted in
patients with total prior docetaxel doses of P225–450 mg/m2
(HR 0. 60; 95% CI 0.43–0.84) and P900 mg/m2 (HR 0.51; 95% CI
0.33–0.79).
All major secondary efﬁcacy endpoints were met in all three tri-
als (Table 2), although because of differences in trial design andTable 2
Comparison of the main efﬁcacy results in the TROPIC [18], COU-AA-301 [19] and AFFIRM
Trial Treatment arms Primary endpoint: median
OS, months
Main
Tum
resp
rate,
TROPIC [18] Cabazitaxel + prednisone vs.
mitoxantrone + prednisone
15.1 vs. 12.7; HR 0.70
(0.59–0.83); P < 0.0001
14.4
P = 0
COU-AA-301
[19]
Abiraterone + prednisone vs.
placebo + prednisone
14.8 vs. 10.9; HR 0.65
(0.54–0.77); P < 0.001a
14.0
P < 0
AFFIRM [21] Enzalutamide vs. placebo 18.4 vs. 13.6; HR 0.63
(0.53–0.75); P < 0.001
29 v
P < 0
95% conﬁdence intervals reported for hazard ratios.
HR, hazard ratio; OS, overall survival; PFS, progression-free survival; PSA, prostate-spec
a Updated OS analysis:15.8 months for abiraterone vs. 11.2 months for placebo; HR 0
b In patients with measurable disease.
c Reduction in serum PSA by P50%.
d Progression deﬁned as either PSA progression, tumor progression or pain progression
e Radiographic progression.deﬁnition of endpoints, data cannot be directly compared. Of note,
unlike the COU-AA-301 and AFFIRM trials, in which progression
was deﬁned as radiographic progression (by RECIST) only, progres-
sion in TROPIC was deﬁned as any of several criteria, resulting in a
relatively short duration of PFS (2.8 months for cabazitaxel plus
prednisone vs. 1.4 months for mitoxantrone plus prednisone;
P < 0.0001) [18] (Table 2). In routine clinical practice, the deﬁnition
of progression is likely to be somewhere between these two deﬁni-
tions, probably based on two of the three factors (PSA progression,
tumor progression and pain progression). Time to tumor progres-
sion in TROPIC (by RECIST only) in patients with measurable dis-
ease (8.8 months for cabazitaxel plus prednisone [n = 201] vs.
5.4 months for mitoxantrone plus prednisone [n = 204];
P < 0.0001) was longer than PFS in the overall patient population,
[18] and was similar to the PFS durations seen in the other trials
(COU-AA-301: 5.6 months for AA plus prednisone vs. 3.6 months
for placebo plus prednisone, P < 0.001 [19]; AFFIRM: 8.3 months
for enzalutamide vs. 2.9 months for placebo, P < 0.001) (Table 2).
In AFFIRM, the time to ﬁrst SRE was signiﬁcantly prolonged in
the enzalutamide group compared with placebo (16.7 months vs.
13.3 months, P < 0.001) [21]. In COU-AA-301, the proportion of pa-
tients with SRE was similar across the two treatment groups. How-
ever, the median time to ﬁrst SRE was signiﬁcantly longer in the AA
arm than in the placebo arm (25.0 months vs. 20.3 months;
P = 0.0001) [27]. Time to ﬁrst SRE was not evaluated in the TROPIC
trial [18].
Interestingly, pain response rate and time to pain progression
were similar in the cabazitaxel and mitoxantrone groups in the
TROPIC trial [18]. As mitoxantrone is an established palliative care
option in this treatment setting, this suggests that cabazitaxel may
have important palliative effects in addition to the OS beneﬁt pro-
vided. In COU-AA-301, AA plus prednisone was associated with a
higher rate of palliation of both pain intensity (45.0% vs. 28.8%,
respectively; P = 0.0005) and pain interference with daily activities
(60.1% vs. 38.0%, respectively; P = 0.0002) than placebo plus pred-
nisone [27]. The AA arm was also superior to the placebo arm on
several other measures of pain response. These included median
time to palliation of pain intensity and pain interference, median
time to progression of pain intensity and pain interference, and
median duration of pain palliation [27]. Pain response/progression
were not included as secondary endpoints in the AFFIRM trial [21].
Fatigue is commonly observed in patients with advanced pros-
tate cancer [28]. The COU-AA-301 trial was the ﬁrst Phase III trial
in advanced prostate cancer to include an assessment of the effect
of administered treatments on patient-reported fatigue intensity
and fatigue interference with daily activities [29]. AA plus predni-
sone was shown to signiﬁcantly increase the proportion of patients[21] trials.
secondary efﬁcacy endpoints
or
onse
%b
PSA response
rate, %c
Median PFS, months Median time to PSA
progression, months
vs. 4.4;
.0005
39.2 vs. 17.8;
P = 0.0002
2.8 vs. 1.4;d HR 0.74
(0.64–0.86) P < 0.0001
6.4 vs. 3.1; HR 0.75
(0.63–0.90) P = 0.001
vs. 2.8;
.0001
29.1 vs. 5.5;
P < 0.001
5.6 vs. 3.6;e HR 0.67
(0.59–0.78) P < 0.001
10.2 vs. 6.6; HR 0.58
(0.46–0.73) P < 0.001
s. 4;
.001
54 vs. 2;
P < 0.001
8.3 vs. 2.9;e HR 0.40
(0.35–0.47) P < 0.001
8.3 vs. 3.0; HR 0.25
(0.20–0.30) P < 0.001
iﬁc antigen.
.74; P < 0.0001 [25].
. Time to tumor progression was 8.8 vs 5.4 months; HR 0.61 (0.49–0.76); P < 0.0001.
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respectively; P = 0.0001) and improved fatigue interference
(55.0% vs. 38.0%, respectively; P = 0.0075) compared with placebo
plus prednisone [29]. Time to progression of fatigue was also sig-
niﬁcantly prolonged in the AA arm compared with the placebo
arm. Measures of fatigue were not included in the AFFIRM or TRO-
PIC trials [18,21].
The QoL response rate, assessed by the Functional Assessment
of Cancer Therapy-Prostate (FACT-P) questionnaire [30], was in-
creased vs. placebo in the AFFIRM trial (43% for enzalutamide vs.
18% for placebo; P < 0.001). Although QoL data were collected in
the COU-AA-301 trial, these have not yet been reported. QoL data
were not collected in the TROPIC study.
Safety
A comparison of the main safety results of the TROPIC, COU-AA-
301 and AFFIRM trials is shown in Table 3. The TROPIC trial dem-
onstrated that cabazitaxel treatment was associated with hemato-
logic and gastrointestinal AEs, manageable with prophylactic
granulocyte-colony stimulating factor (G-CSF) use and proactive
patient monitoring [18]. G-CSF and loperamide support for pa-
tients with neutropenia or diarrhea, respectively, was speciﬁed in
the study protocol, with the exception of use during Cycle 1. Other
AEs reported in the TROPIC trial were consistent with those ex-
pected for taxane-based therapies such as docetaxel and paclitaxel.
Anemia was the most common AE in the cabazitaxel group (all
grades, 97% in the cabazitaxel group vs. 81% in the mitoxantrone-
group; GradeP 3, 11% vs. 5%), followed by leukopenia (all grades,
96% vs. 92%; GradeP 3, 68% vs. 42%) and neutropenia (all grades,Table 3
Comparison of the main safety results in the TROPIC [18], COU-AA-301 [19] and AFFIRM
Adverse event TROPIC (cabazitaxel + prednisone arm;
n = 371)
COU-AA
n = 791
Hematologic All grades GradesP 3 All grad
Anemia 361 (97) 39 (11) 178 (23
Thrombocytopenia 176 (47) 15 (4) 28 (4)
Leukopenia 355 (96) 253 (68) N/A
Neutropenia 347 (94) 303 (82) 7 (1)
Febrile neutropenia 0 28 (8) 0
Non-hematologic
Abdominal pain 43 (12) 7 (2) 95 (12)
Arthralgia 39 (11) 4 (1) 215 (27
Asthenia 76 (20) 17 (5) 104 (13
Back pain 60 (16) 14 (4) 233 (30
Bone pain 19 (5) 3 (1) 194 (25
Cardiac disorder N/A 106 (13
Constipation 76 (20) 4 (1) 206 (26
Diarrhea 173 (47) 23 (6) 139 (18
Dyspnea 44 (12) 5 (1) 102 (13
Fatigue 136 (37) 18 (5) 346 (44
Fluid retention and edema N/A N/A 241 (31
Headache N/A N/A N/A
Hematuria 62 (17) 7 (2) 65 (8)
Hypertension N/A N/A 77 (10)
Hypokalemia N/A N/A 135 (17
Hot ﬂash N/A N/A N/A
Liver function abnormalityb N/A N/A 81 (10)
Musculoskeletal pain N/A N/A N/A
Nausea 127 (34) 7 (2) 233 (30
Pain 20 (5) 4 (1) 13 (2)
Pain in arm or leg N/A N/A 134 (17
Pain in extremity 30 (8) 6 (2) N/A
Pyrexia 45 (12) 4 (1) 71 (9)
Seizure N/A N/A N/A
Urinary tract infection 27 (7) 4 (1) 91 (12)
Vomiting 84 (23) 7 (2) 168 (21
N/A = not available.
a These data are adverse events that occurred in more than 10% of patients in the enz
b Included hyperbilirubunemia and increased levels of aspartate amino transferase.94% vs. 88%; GradeP 3, 82% vs. 58%) [18]. GradeP 3 febrile neu-
tropenia occurred in 8% of patients receiving cabazitaxel and 1%
of patients receiving mitoxantrone. The most common non-hema-
tologic AEs were diarrhea (all grades, 47% in the cabazitaxel group
vs. 11% in the mitoxantrone group; GradeP 3, 6% vs. <1%) and fa-
tigue (all grades, 37% vs. 27%; GradeP 3, 5% vs. 3%). Grade 3
peripheral neuropathy was uncommon (1% in both treatment
groups). Eighteen percent of patients discontinued treatment due
to AEs in the cabazitaxel group compared with 8% in the mitoxan-
trone group. Dosereductions occurred in 10% of patients receiving
cabazitaxel compared with 5% of patients receiving mitoxantrone.
Total deaths during the study were 227 (61%) in the cabazitaxel
group compared with 275 (74%) in the mitoxantrone arm. The
most frequent cause of death due to AEs in the cabazitaxel group
was neutropenia and its clinical consequences/sepsis (7 patients
[2%] compared with 1 patient [<1%] in the placebo group).
Interim results (n = 919) from a compassionate-use program
and expanded-access program of cabazitaxel plus prednisone in
patients with mCRPC previously treated with docetaxel reported
lower rates of AEs (including febrile neutropenia) compared with
TROPIC [31]. The most common relevant Grade 3/4 AEs possibly re-
lated to cabazitaxel were febrile neutropenia (6.1%), fatigue (3.6%),
diarrhea (3.0%) and nausea (1.0%) (n = 919).
The COU-AA-301 study demonstrated that urinary tract infec-
tions were more common in patients who received AA compared
with patients who received placebo (all grades, 12% vs. 7%; Grade
3, 2% vs. <1%) [19]. Furthermore, treatment with AA was associated
with elevated mineralocorticoid levels; ﬂuid retention and edema
were increased in the AA group compared with placebo (all grades,[21] trials.
-301 (abiraterone + prednisone arm;
)
AFFIRM (enzalutamide arm;
n = 800)
es Grades 3/4 All grades GradesP 3
) 59 (7) N/A N/A
11 (1) N/A N/A
N/A N/A N/A
1 (<1) N/A N/A
0 N/A N/A
16 (2) N/A N/A
) 33 (4) N/A N/A
) 18 (2) N/A N/A
) 47 (6) N/A N/A
) 44 (6) N/A N/A
) 33 (4) 49 (6) 7 (1)
) 8 (1) N/A N/A
) 5 (<1) 171 (21)a 9 (1)a
) 10 (1) N/A N/A
) 66 (8) 269 (34)a 50 (6)a
) 18 (2) N/A N/A
93 (12)a 6 (<1)a
11 (1) N/A N/A
10 (1) N/A N/A
) 30 (4) N/A N/A
162 (20)a 0a
27 (3) 8 (1) 3 (<1)
109 (14)a 8 (1)a
) 13 (2) N/A N/A
5 (1) N/A N/A
) 19 (2) N/A N/A
N/A N/A N/A
3 (<1) N/A N/A
N/A 5 (<1) 5 (<1)
17 (2) N/A N/A
) 14 (2) N/A N/A
alutamide group, and at a rate of at least 2% higher than in the placebo group.
A. Bahl et al. / Cancer Treatment Reviews 40 (2014) 170–177 17531% vs. 22%; Grade 3, 2% vs. 1%; Grade 4, <1% vs. 0%) [19]. In pa-
tients who develop this AE, use of prednisone may not be advisable
because of its intrinsic mineralocorticoid activity. AA treatment
was also associated with elevated aminotransferase levels, result-
ing in a protocol amendment that speciﬁed more frequent liver
function monitoring during the trial [19]. The most common AEs
reported in the COU-AA-301 trial were fatigue (all grades, 44% in
the AA group vs. 43% in the placebo group; Grade 3, 8% vs. 9%;
Grade 4, <1% vs. 1%), back pain (all grades, 30% vs. 33%; Grade 3,
6% vs. 9%; Grade 4, <1% vs <1%) and nausea (all grades, 30% vs.
32%; Grade 3, 2% vs. 3%; Grade 4, <1% vs. 0%). AEs leading to treat-
ment discontinuation occurred with similar frequency in both
groups (19% in the AA group vs. 23% in the placebo group). The
incidence of dose modiﬁcations due to AEs was also similar in both
groups. In total, there were 333 deaths (42%) in the AA group and
219 deaths (55%) in the placebo group. Fewer AE-related deaths
were reported in the AA group than in the placebo group (12%
vs. 15%). Eleven percent of patients (actual numbers not reported)
in the AA group and 13% of patients (actual numbers not reported)
in the placebo group died within 30 days of last dose of study med-
ication, themajority of whom died due to disease progression, indi-
cating that time available to administer another treatment is
limited.
In the AFFIRM trial, overall rates of AEs were similar in the enza-
lutamide and placebo groups, although rates of fatigue (all grades,
34% vs. 29%; GradeP 3, 6% vs. 7%), diarrhea (all grades, 21% vs.
18%; Grade 3, 1% vs. <1%), hot ﬂashes (all grades, 20% vs. 10%),
musculoskeletal pain (all grades, 14% vs. 10%; Grade 3, 1% vs.
<1%) and headache (all grades, 12% vs. 6%; Grade 3, <1% vs. 0%)
were higher in the enzalutamide group compared with the placebo
group [21]. Seizure was reported in 0.6% of patients in the enzalu-
tamide group, whereas it was not reported in the placebo group
[21]. Of the patients who experienced seizures in the enzalutamide
group, several had factors potentiallypredisposing to seizure [21].
These results suggest that enzalutamide may not be the most
appropriate agent for use in patients at risk of seizure. Eight per-
cent of patients discontinued due to an AE in the enzalutamide
group compared with 10% in the placebo group. The median time
to the ﬁrst Grade 3 AE was 12.6 months in the enzalutamide
group compared with 4.2 months in the placebo group. There were
308 deaths (39%) in the enzalutamide group and 212 deaths (53%)
in the placebo group. AEs leading to death occurred in 23 patients
(3%) in the enzalutamide group and 14 patients (4%) in the placebo
group.Ongoing and recently completed studies of approved second-
line agents in mCRPC
A trial of AA as a ﬁrst-line treatment for mCRPC (COU-AA-302)
has recently been published [32]. In the trial, 1088 chemotherapy-
naïve, asymptomatic or mildly symptomatic patients were ran-
domized to receive AA (1 g orally, once daily) plus prednisone
(5 mg orally, twice daily) or placebo plus prednisone (5 mg orally,
twice daily) [32]. The co-primary endpoints were radiographic PFS
and OS. After favorable interim results, the study was unblinded
and patients receiving placebo were crossed over to receive active
treatment. At the time of interim analysis, the median radiographic
PFS was 16.5 months in the AA group compared with 8.3 months in
the placebo group (HR 0.53; 95% CI 0.45–0.62; P < 0.001). Median
OS had not been reached in the AA group, and was 27.2 months
(HR 0.75; 95% CI 0.61–0.93; P = 0.01) in the placebo group [32].
Based on results from this trial, AA has been approved by the
FDA in combination with prednisone in the treatment of late-stage,
castration-resistant prostate cancer before chemotherapy.First-line enzalutamide is also being evaluated in a large, pla-
cebo-controlled Phase III trial in 1680 chemotherapy-naïve pa-
tients with progressive mCRPC (PREVAIL; NCT01212991). The
primary endpoints are OS and PFS; secondary endpoints include
time to ﬁrst SRE and time to initiation of cytotoxic therapy. The
trial is reported to complete in 2014.
A large, open-label, randomized, Phase III dose-optimization
trial of cabazitaxel in the docetaxel-refractory mCRPC setting is
ongoing (NCT01308580). The PROSELICA study will randomize
1200 patients to receive cabazitaxel 20 or 25 mg/m2 IV every
3 weeks plus prednisone (10 mg orally, once daily) [33]. The pri-
mary endpoint is OS, and secondary endpoints include PFS, PSA
progression and response, pain progression and response, tumor
response, health-related QoL, safety, pharmacokinetics and phar-
macogenomics. The trial is estimated to complete in 2017.
Cabazitaxel is also being evaluated in a ﬁrst-line Phase III trial
(FIRSTANA; NCT01308567). In this open-label trial, 1170 patients
with chemotherapy-naïve mCRPC will be randomized to docetaxel
(75 mg/m2 every 3 weeks) or cabazitaxel (20 or 25 mg/m2 every
3 weeks) plus prednisone (10 mg orally, daily). The primary end-
point is OS and secondary endpoints include PFS, PSA progres-
sion-free survival, pain progression-free survival, tumor response,
PSA response, pain response, time to ﬁrst SRE, health-related
QoL, pharmacokinetics and pharmacogenomics. The trial is esti-
mated to complete in 2017.
A Phase I/II dose-escalation study of cabazitaxel (every 3 weeks)
plus AA (1 g orally, daily) and prednisone (10 mg orally, daily) is
also ongoing in 38 patients with mCRPC whose disease has pro-
gressed after treatment with docetaxel (NCT01511536). The pri-
mary endpoints are the maximum tolerated dose and PSA
response rate. Secondary endpoints include safety, objective PFS,
PSA progression-free survival, objective response rate, OS and
pharmacokinetics. This study, estimated to be completed in 2014,
will potentially provide important information on the use of these
agents in combination in this setting.Overview of additional agents approved or in development for
patients with mCRPC
Several Phase III trials of investigational agents in the second-
line mCRPC setting are ongoing (Table 4). Initial results of a dou-
ble-blind, randomized, Phase III trial of radium-223 (ALSYMPCA;
ALpharadin in SYMptomatic Prostate CAncer patients) have been
reported [16,17]. In the trial, 921 patients with mCRPC and P2
bone metastases, who were either previously treated with doce-
taxel or were unsuitable for, or declined, docetaxel, were random-
ized 2:1 to receive radium-223 treatment (50 kBq/kg; six IV
administrations separated by 4-week intervals) plus best support-
ive care, or placebo plus best supportive care [16,17]. Radium-223
was found to improve OS compared with placebo and the study
was terminated early at the request of the IDMC [34]. An analysis
performed before patients in the placebo arm were crossed over to
active treatment found a median OS of 14.9 months in the radium-
223 group vs. 11.3 months in the placebo group (HR 0.70; 95% CI
0.58–0.83; P = 0.00007) [17]. Several secondary efﬁcacy endpoints
were also met, including a signiﬁcant increase in time to ﬁrst SRE
compared with placebo (median 13.6 months vs. 8.4 months; HR
0.61; 95% CI 0.461–0.807; P = 0.00046) [35]. Because the ALS-
YMPCA trial included only patients with P2 bone metastases
and excluded patients with visceral metastases, the patient popu-
lation differed to those of the TROPIC, COU-AA-301 and AFFIRM tri-
als [17]. Safety and tolerability of radium-233 were favorable;
however, hematologic AEs, although rare, were increased in pa-
tients who received radium-223 [17]. Grade 3/4 neutropenia oc-
curred in 2.2% and 0.7% of the radium-223 and placebo groups,
Table 4
Agents in Phase III randomized trials for metastatic castration-resistant prostate cancer progressing on or after docetaxel therapy.
Agent and trial Class Design N Treatment arms Patient population Primary
endpoint
Main secondary endpoints
Radium-223 (50 kBq/
kg IV every 4 weeks)
ALSYMPCA
(NCT00699751)
[16,17]
Targeted
alpha-
emitter
DB 921 Radium-223 + BSC vs.
placebo + BSC
Symptomatic CRPC with P2
bone metastases, either post-
docetaxel or unsuitable for/
declined docetaxel
OS  Time to ﬁrst SRE.
 Safety
Orteronel (400 mg BID)
C21005
(NCT01193257) [36]
17,20-lyase
inhibitor
DB 1083a Orteronel + prednisone
vs.
placebo + prednisone
mCRPC that has progressed
during or following docetaxel
OS  Radiographic PFS.
 PSA decrease of P50% at 12
weeks.
 Pain response at 12 weeks.
 Safety.
 Time to PSA progression.
 Objective response.
 Circulating tumor cells and
endocrine marker changes.
 PROs.
Ipilimumab (10 mg/kg
IV every 3 weeks)
CA184-043
(NCT00861614) [37]
Anti-CTLA-4
monoclonal
antibody
DB 800a RT + ipilimumab vs.
RT + placebo
mCRPC with progression on or
within 6 months of docetaxel;
P1 bone metastases appropriate
for RT; ECOG PS 0–1
OS  PFS.
 Pain response.
 Safety.
BID, twice daily; BSC, best standard of care; DB, double blind; ECOG, European Cooperative Oncology Group; IV, intravenous; mCRPC, metastatic castration-resistant prostate
cancer; OS, overall survival; PFS, progression-free survival; PROs, patient-reported outcomes; PS, performance status; PSA, prostate-speciﬁc antigen; RT, radiotherapy; SRE,
skeletal-related event.
a Planned enrollment.
176 A. Bahl et al. / Cancer Treatment Reviews 40 (2014) 170–177respectively, and Grade 3/4 thrombocytopenia occurred in 6.3%
and 2% [17]. A full publication reporting the primary ﬁndings from
the ALSYMPCA trial is awaited before the data can be evaluated
further. However, the fact that the trial included patients unsuit-
able for, or who declined, docetaxel has important implications
for the patient population who will likely derive beneﬁt from this
agent in clinical practice.Summary and conclusions
The TROPIC, COU-AA-301 and AFFIRM trials have all reported
signiﬁcant improvements in OS in patients with mCRPC in the sec-
ond-line setting. Patients now have several treatment options
post-docetaxel, including the three agents evaluated in these trials
(cabazitaxel, AA and enzalutamide). These developments represent
major progress and have changed the standard of care. In the ab-
sence of sequencing data, clinicians need to decide which therapies
to use based on existing evidence. Differences in study designs
make it difﬁcult to draw cross-trial comparisons.
However, more detailed information on patient baseline and
disease characteristics, together with additional sequencing stud-
ies, may allow clinicians to identify speciﬁc populations that will
beneﬁt most from different drugs. For example, for patients who
have not received prior docetaxel treatment, several agents have
demonstrable activity, including abiraterone, enzalutamide and ra-
dium-223. These agents may be preferable to chemotherapy both
in patients with asymptomatic disease and in patients with factors
predisposing to poor tolerance of chemotherapy. On the other
hand, for patients with rapidly progressing disease or visceral
metastases, or patients with a poor response to initial androgen
deprivation therapy, the use of chemotherapy may be preferred.
A study investigating the use of cabazitaxel in the ﬁrst-line setting
is underway. For patients who have received prior docetaxel ther-
apy, approved choices include abiraterone, cabazitaxel, enzaluta-
mide and radium-223. In the absence of robust sequencing data
and treatment guidelines, treatment choice may be guided by drug
availability together with physician experience. In addition, patient
characteristics such as performance status and response to and
toxicities experiences with prior regimens should also be assessed.
Across all treatment settings, it is reasonable that patients at risk ofspeciﬁc AEs should avoid certain agents; for example, patients at
risk of seizure may be better suited to cabazitaxel or AA, rather
than enzalutamide. As patients with mCRPC are a heterogeneous
population, and the disease is highly dynamic, an adaptive ap-
proach may be required.
Systemic treatment for prostate cancer is changing rapidly and
new treatments are already improving outcomes for men with
mCRPC. Additional studies are needed to optimize the use of these
agents by identifying those patients who most beneﬁt and discov-
ering the best way of giving them either in combination or as
sequential single agents. Consideration of optimal sequencing
strategies is important to maximize use of available therapies. In
particular, switching to next treatment early upon disease progres-
sion is important to optimize patient beneﬁt from all suitable ther-
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